Quantum BioPharma Debt to Equity

Quantum BioPharma (QNTM) currently reports a debt-to-equity ratio of 0.12. That is below the sector sector average of 0.2. Use the charts on this page to explore Quantum BioPharma's debt-to-equity ratio history and peer comparisons.

Quantum BioPharma's debt-to-equity ratio of 0.12 is lower than the its sector sector average of 0.2. That is roughly 39.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Quantum BioPharma's market price to a fundamental measure such as earnings, sales, or book value. At 0.12, QNTM can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 0.12, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 0.2. From there, open related valuation or income-statement pages for Quantum BioPharma, and consider following QNTM for alerts when major investors trade the stock.